Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


TEVA

Teva Gets Final OK for Generic Prevacid Delayed-Release Capsules - 11/13 - 12:21 AM ET

Teva wins FDA approval for generic acid reflux drug - 11/12 - 09:56 AM ET

Teva wins lawsuit for generic acid reflux drug - 11/12 - 09:54 AM ET

Teva Gets Court Decision Regarding Generic Prevacid SoluTab - 11/12 - 12:19 AM ET

Teva gets FDA, court nods for generic Prevacid: US sales of Prevacid Delayed-Release Capsules are $2.97 billion a year. - 11/11 - 03:45 PM ET

Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules - 11/10 - 04:17 PM ET

Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab - 11/10 - 09:46 AM ET

Teva Releases Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets - 11/05 - 10:58 PM ET

Teva Pharmaceutical launches generic allergy tablets - 11/05 - 10:00 AM ET

BRIEF: Teva launches genetic allergy drug in US: Annual US sales of the original drug, sanofi-aventis's Allegra-D, are $293 million. - 11/04 - 04:49 PM ET

TASE drops below 1,000: Merrill Lynch analyst Haim Israel: The TASE is correcting, and it will last a few weeks. - 11/03 - 04:32 PM ET

Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D(R) 12 Hour Tablets - 11/03 - 03:35 PM ET

Teva Pharmaceutical Industries Beats By a Penny, Revenue up 25% (TEVA) - 11/03 - 09:41 AM ET

Teva Reports Third Quarter 2009 Results - 11/03 - 01:30 AM ET

BRIEF: Will Pfizer buy Protalix?: Pfizer representatives have visited Protalix Biotherapeutics in Carmiel in the past few days. - 11/01 - 04:56 PM ET

MultiGene Vascular Systems (MGVS) secures $8.5 million in venture funding round - 10/30 - 02:42 PM ET

Teva leads $8.5m financing round for vascular co MGVS: MGVS will use the proceeds to finance the Phase I/IIa clinical trial of its Multi Gene Graft biosynthetic vascular graft. - 10/27 - 04:35 PM ET

Hapoalim: Teva to make acquisition in H1 of 2010: Gilad Sarig: There is little chance that generic Copaxone will hit the market before 2012. - 10/27 - 04:34 PM ET

Rumors focus on Teva acquisition of Protalix: Protalix CEO; We will only sell if we receive an exceptional offer we cannot refuse. - 10/25 - 07:12 PM ET

Teva increases lobbying expenditure in 2009: However, the pharmaceutical company's third quarter lobbying expenditure was down. - 10/21 - 03:58 PM ET

Page 1 of 13     1  2   3   4   5   >   >>|     Previous  |  Next

<< Back to Stock Index

 

Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.